In a series of presentations at the 2021 virtual meeting of the North American Neuromodulation Society, Lynn R. Webster, MD, and his colleagues concluded that the novel agent was not associated with significantly decreased respiratory drive and also may have a lower risk for abuse potential than oxycodone.